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Review
The role of hybrid ubiquitin chains in the MyD88 and
other innate immune signalling pathways
Philip Cohen*,1 and Sam Strickson1
The adaptor protein MyD88 is required for signal transmission by toll-like receptors and receptors of the interleukin-1 family of
cytokines. MyD88 signalling triggers the formation of Lys63-linked and Met1-linked ubiquitin (K63-Ub, M1-Ub) chains within
minutes. The K63-Ub chains, which are formed by the E3 ubiquitin ligases TRAF6, Pellino1 and Pellino2, activate TAK1, the master
kinase that switches on mitogen-activated protein (MAP) kinase cascades and initiates activation of the canonical IκB kinase (IKK)
complex. The M1-Ub chains, which are formed by the linear ubiquitin chain assembly complex (LUBAC), bind to the NEMO (NF-κB
essential modulator) component of the IKK complex and are required for TAK1 to activate IKKs, but not MAP kinases. An essential
E3 ligase-independent role of TRAF6 is to recruit LUBAC into the MyD88 signalling complex, where it recognises preformed K63-Ub
chains attached to protein components of these complexes, such as IRAK1 (IL-1 receptor-associated kinase), producing ubiquitin
chains containing both types of linkage, termed K63/M1-Ub hybrids. The formation of K63/M1-Ub hybrids, which is a feature of
several innate immune signalling pathways, permits the co-recruitment of proteins that interact with either K63-Ub or M1-Ub
chains. Two likely roles for K63/M1-Ub hybrids are to facilitate the TAK1-dependent activation of the IKK complex and to prevent the
hyperactivation of these kinases by recruiting A20 and A20-binding inhibitor of NF-κB1 (ABIN1). These proteins restrict activation
of the TAK1 and IKK complexes, probably by competing with them for binding to K63/M1-Ub hybrids. The formation of K63/M1-Ub
hybrids may also regulate the rate at which the ubiquitin linkages in these chains are hydrolysed. The IKK-catalysed
phosphorylation of some of its substrates permits their recognition by the E3 ligase SCFβTRCP, leading to their Lys48-linked
ubiquitylation and proteasomal degradation. Innate immune signalling is therefore controlled by the formation and destruction of
three different types of ubiquitin linkage.
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Facts
 The activation of toll-like receptors (TLR) and the
interleukin-1 (IL-1) receptor triggers the rapid formation of
Lys63-linked and Met1-linked ubiquitin oligomers.
 The Lys63-linked and Met1-linked ubiquitin oligomers are
required to activate the TAK1 and canonical IκB kinase
complexes, respectively.
 TheMet1-linked ubiquitin oligomers are attached covalently
to preformed Lys63-linked ubiquitin oligomers, generating
Lys63/Met1 ubiquitin hybrids.
 The Lys63/Met1 ubiquitin hybrids can recruit proteins that
bind to either Lys63-linked or Met1-linked ubiquitin
oligomers.
Open Questions
 Which E3 ligases generate the Lys63-linked ubiquitin
chains that are required for the activation of TAK1 and the
formation of Lys63/Met1 ubiquitin hybrids?
 In the TLR and IL-1R signalling pathways, how is LUBAC
(linear ubiquitin chain assembly complex) able to use
Lys63-linked ubiquitin oligomers as its preferred initial
substrate, rather than monomeric ubiquitin?
 How is the TLR- or IL-1R-dependent formation of Met1-
linked ubiquitin chains regulated?
 What roles do Lys63/Met1-linked ubiquitin hybrids play in
innate immune signalling pathways?
Lys63-Linked Ubiquitin Oligomers Activate the Protein
Kinase TAK1
The role of Lys48-linked ubiquitin (K48-Ub) oligomers in
triggering protein degradation by the proteasome was worked
out between 1978 and 1989,1,2 but it was not until the mid
1990s that cellular roles for other types of Ub oligomers began
to emerge. In 1995, yeast expressing the Ub[K63R] mutation
were shown to be hypersensitive to ultraviolet irradiation and
failed tomake a particular subset of ubiquitin conjugates.3 This
provided indirect evidence that K63-Ub oligomers were
involved in DNA repair, but direct evidence was only obtained
4 years later when Ubc13, a protein known to be required for
DNA repair, was shown to assemble K63-Ub chains specifi-
cally in the presence of yeast orthologues of the mammalian
protein Uev1a.4 The same paper also provided genetic
evidence that the enhanced UV sensitivity of yeast expressing
Ubc13 mutants was caused by the failure to synthesise these
ubiquitin chains.
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Soon after, tumour necrosis factor receptor-associated
factor 6 (TRAF6), a protein whose expression is essential for
interleukin-1 (IL-1) and toll-like receptor (TLR) signalling,5–7
was shown to possess E3 ubiquitin ligase activity, which in
combination with the Ubc13-Uev1a E2-conjugating complex
catalysed the specific formation of Lys63-linked ubiquitin
(K63-Ub) chains.8 Even more importantly, the TRAF6-
generated K63-Ub chains were found to activate a protein
kinase in vitro, which could in turn activate the canonical IκB
kinase (IKK) complex and MAP kinase kinase 6 (MKK6)
in vitro. It was purified and identified as the TAK1 (transforming
growth β-activated kinase 1) complex, comprising the TAK1
catalytic subunit, TAK1-binding protein 1 (TAB1) and TAB2.9
Subsequently TAB3, a TAB2-related protein, was identified10
and it became clear that two TAK1 complexes (TAB1–TAK1–
TAB2 and TAB1–TAK1–TAB3) are expressed in cells.11 The
essential role of TAK1 in mediating the IL-1-dependent
activation of the canonical IKK complex and MAP kinases
was demonstrated by studies in embryonic fibroblasts from
TAK1 knockout (KO) mice12 or knock-in mice lacking TAK1
catalytic activity.13
The C-termini of TAB2 and TAB3 possess Npl4 zinc fingers
(NZF) that bind to K63-Ub chains specifically and are essential
for the activation of TAK1 in vitro.14,15 Thus the idea emerged
that TRAF6-generated K63-Ub chains interact with TAB2 or
TAB3 inducing a conformational change that activates the
TAK1 catalytic subunit. This allosteric mechanism is similar to
the activation of cyclic AMP-dependent protein kinase (PKA)
by cyclic AMP or calmodulin-dependent protein kinases by
calcium ions.
How MyD88 Signalling Activates the E3 Ligases TRAF6
and Pellino
Myeloid differentiation primary response gene 88 (MyD88) is
an adaptor protein required for signal transduction by TLRs
and receptors of the IL-1 family of cytokines (IL-1, IL-18 and
IL-33). The interaction of components of microbial pathogens
with TLRs or IL-1 with the IL-1R recruits MyD88 to the
receptors, and then members of the IL-1 receptor-associated
kinase (IRAK) family to MyD88 through a series of death
domain (DD) interactions. The DD of IRAK4 interacts with the
DD of MyD88 and the DDs of IRAK1 and/or IRAK2 with
the DD of IRAK4, forming oligomeric complexes termed
Myddosomes.16,17 TRAF6 interactswith Pro-Xaa-Glumotifs in
the C-terminal regions of IRAK1 and IRAK2, triggering the
dimerisation of the RING domain of TRAF618 and the
activation of its E3 ligase activity (Figure 1).19 In contrast to
TRAF6, the Pellino family of E3 ligases is activated by IRAK-
catalysed phosphorylation. They can be activated in vitro by
IRAK1 or IRAK420,21 and the IL-1-dependent activation of
Pellino1 is suppressed in embryonic fibroblasts from knock-in
mice expressing a kinase-inactive mutant of IRAK1 or in
human cells treated with an IRAK1 inhibitor.22 Like TRAF6, the
Pellino E3 ligases can combinewith Ubc13-Uev1a to generate
K63-Ub chains in vitro.20,21
It is widely accepted that the E3 ligase activity of TRAF6 is
essential for MyD88 signalling. However, we have found that
E3 ligase-inactive mutants of TRAF6 partially restore IL-1 and
TLR signalling when they are re-expressed in TRAF6 KO
human cells, but not in TRAF6 KO cells that also lack
expression of Pellino1 and Pellino2. Moreover, we have
generated a knock-in mouse in which TRAF6 is replaced by
an E3 ligase-inactive mutant, and shown that MyD88
signalling is reduced, but not abolished in primary macro-
phages and embryonic fibroblasts from these mice.23 These
and other findings indicate that TRAF6, Pellino1 and Pellino2
contribute to the MyD88-dependent formation of K63-Ub
chains in some cells (Figure 1), and that the essential roles of
TRAF6 in this pathway are independent of its E3 ligase activity.
Met1-Linked Ubiquitin Oligomers and the MyD88-
Dependent Activation of the Canonical IKK Complex
The canonical IKK complex comprises the related protein
kinases IKKα and IKKβ, and a regulatory component called
NF-κB essential modulator (NEMO).24,25 NEMO possesses
an ubiquitin-binding domain that was initially shown to interact
with K63-Ub oligomers.26,27 Mutations in this domain, such as
NEMO[D311N], prevent binding to ubiquitin oligomers, impair
activation of the canonical IKK complex and cause X-linked
recessive anhidrotic ectodermal dysplasia with immunodefi-
ciency in humans.28,29 These findings highlighted the
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Figure 1 How the MyD88 pathway triggers the ubiquitylation of IRAK1. The
interaction of IL-1 with its receptor leads to the formation of the Myddosome and the
phosphorylation and activation of IRAK1. The interaction of IRAK1 with TRAF6
induces dimerisation of the RING domain of TRAF6, activating its E3 ligase function.
IRAK1 also phosphorylates Pellino1 and Pellino2 converting them from inactive to
active E3 ubiquitin ligases. In the presence of E1-activating enzyme and the E2-
conjugating complex Ubc13-Uev1a, TRAF6 and Pellinos 1 and 2 both contribute to
the formation of K63-Ub chains, which become attached to IRAK1 and other
components of the Myddosome. One essential role of TRAF6 is to recruit LUBAC into
the IL-1 signalling complex where it interacts with K63-Ub-substrates, such as IRAK1,
to produce K63/M1-Ub-IRAK1. In the human cell lines we have studied, the
expression of IRAK1 is essential for IL-1 signalling and the IRAK2 in these cells
cannot compensate for the loss of IRAK1. Protein kinases are highlighted in red and
E3 ligases in green
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importance of ubiquitin binding to NEMO for the activation of
the canonical IKK complex in vivo. They also suggested that
K63-Ub chains might function as molecular scaffolds to
co-recruit the IKK and TAK1 complexes, thereby facilitating
the TAK1-dependent activation of the IKKs.26
An unexpected twist to the regulation of the IKK complex
emerged with the discovery of the linear ubiquitin chain
assembly complex (LUBAC), a heterotrimeric complex com-
prising HOIP (the catalytic subunit), HOIL-1 and Sharpin.30–33
LUBAC is a unique E3 ubiquitin ligase, which catalyses the
formation of Met1-linked ubiquitin (M1-Ub) chains (also called
linear ubiquitin chains) in which the N-terminal methionine of
one ubiquitin forms a peptide bond with the C-terminal
carboxylate of another ubiquitin molecule. Significantly, NEMO
was found to bind to M1-Ub dimers with 100-fold higher affinity
than K63-Ub dimers.34,35 Moreover, the IL-1-dependent
formation of M1-Ub chains was abolished (Figure 2a) and
activation of the canonical IKK complex greatly reduced
(Figure 2b) in embryonic fibroblasts from knock-in mice in
which HOIP had been replaced by the E3 ligase-inactive HOIP
[C879S] mutant.36 The IL-1-dependent activation of the
canonical IKK complex was similarly reduced in embryonic
fibroblasts from knock-in mice expressing the NEMO[D311N]
mutant37 (Figure 2b). Thus the LUBAC-catalysed formation of
M1-Ub chains and their binding to NEMO are both required for
robust IL-1-dependent activation of the canonical IKK complex
in murine embryonic fibroblasts (MEFs). The IL-1-dependent
activation of the IKK complex is also impaired in embryonic
fibroblasts from HOIL-1 KO mice, which may be explained by
the greatly reduced expression of HOIP in these cells.38
Consistent with the genetic evidence outlined above, LUBAC-
generated M1-Ub chains restored the activation of the
canonical IKK complex in HeLa cell extracts depleted of these
components, while the overexpression of LUBAC in wild-type
MEFs, but not in NEMO-deficient MEFs, induced NF-κB-
dependent gene transcription.39
The activation of IKKα and IKKβ requires the phosphoryla-
tion of two amino-acid residues in the activation loops of these
protein kinases (Ser176 and Ser180 of IKKα; Ser177 and
Ser181 of IKKβ).40 More recently the activation of IKKβ was
shown to take place by a two-step mechanism in which TAK1
first phosphorylates IKKβ at Ser177, which is followed by the
IKKβ-catalysed auto-phosphorylation of Ser181.37 The
IL-1-dependent phosphorylation of IKKβ at Ser177 (or IKKα
at Ser176) is impaired in embryonic fibroblasts from the HOIP
[C879S] or NEMO[D311N] mice (Figure 2b). Thus, the
formation of M1-Ub chains and their interaction with NEMO
are both needed for TAK1 to initiate activation of the IKK
complex.37 The interaction of M1-Ub chains with NEMO may
induce a conformational change that permits TAK1 to
phosphorylate Ser176/177 of IKKα/IKKβ.
The formation of M1-Ub chains is not required for the IL-1-
dependent activation of p38α MAP kinase, c-Jun N-terminal
kinase 1 (JNK1) and JNK2.36
The Role of Lys48-Linked Ubiquitylation in MyD88
Signalling
IKKβ activates the transcription factor NF-κB by phosphorylat-
ing its inhibitory (IκB) components. For example, the dual
phosphorylation of IκBα at Ser32 and Ser36 recruits the
SCFβTRCP E3 ligase, leading to Lys48-linked ubiquitylation
and proteasomal degradation of IkBa. The p65 and p50
components of NF-κB can then translocate to the nucleus as a
heterodimer to stimulate the transcription of NF-κB-dependent
genes. IKKβ also phosphorylates the transcription factor IRF5
(interferon regulatory factor 5) at Ser462, inducing its
dimerisation and nuclear translocation where it switches on
the transcription of genes encoding major inflammatory
cytokines, such as IL-1241 and interferon β.42,43 Thus IKKβ
switches on two of the ‘master’ transcription factors required
for inflammatory mediator production (Figure 3).
Another important substrate of IKKβ is the protein kinase
Tpl2 (tumour promotion locus 2). Two heterotrimeric Tpl2
complexes are expressed in cells, comprising the Tpl2L or
Tpl2S catalytic subunits, p105 (also called NF-κB1, the
precursor of the p50 component of NF-κB) and ABIN2
(A20-binding inhibitor of NF-κB2).44 Tpl2L and Tpl2S are
products of the same gene, and arise from the use of
alternative initiation start sites at Met1 (Tpl2L) or Met30
(Tpl2S).
45 IKKβ has a dual role in the activation of Tpl2. First it
phosphorylates p105 at Ser927 and Ser932, leading to the
SCFβTRCP-catalysed Lys48-linked ubiquitylation of p105 and
its proteasomal degradation;46,47 second it phosphorylates
Tpl2L at Ser400, which is followed by the Tpl2-catalysed
phosphorylation of Ser443 and its interaction with 14-3-3
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Figure 2 The formation of M1-Ub chains and their interaction with NEMO are required for TAK1 to initiate the activation of the canonical IKK complex. (a) IL-1 a induces the
formation of M1-Ub chains in embryonic fibroblasts from wild-type (WT) mice, but not in knock-in mice expressing the E3 ligase-inactive HOIP[C879S] mutant. (b) The
IL-1a-dependent, TAK1-catalysed phosphorylation of IKKβ at Ser177 is suppressed in embryonic fibroblasts from HOIP[C879S] knock-in mice that do not form M1-Ub chains,
or in embryonic fibroblasts from NEMO[D311N] knock-in mice in which M1-Ub chains are formed, but are unable to interact with NEMO. Adapted from Emmerich et al.36 and
Zhang et al.37
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proteins. The activated Tpl2L is subsequently ubiquitylated
and degraded by the proteasome.46,47 In contrast, Tpl2S is not
degraded and is presumably responsible for maintaining Tpl2
activity at a lower level for the prolonged period (4–8 h) needed
to produce substantial amounts of pro-inflammatory cytokines
in myeloid cells.
The substrates of Tpl2 identified so far are MKK family
members, namely MAP kinase or ERK kinase 1 (MEK1),
MEK2, MKK3 and MKK6 (Figure 3). MEK1 and MEK2
activate ERK1 and ERK2 (extracellular signal-regulated
kinases 1 and 2).48 MKK3 and MKK6 are rate limiting for the
activation of p38α MAP kinase in some cells, but not in others
cells where MKK4 can activate p38αMAP kinase if MKK3 and
MKK6 are not activated49 (Figure 3). ERK1/2 and p38α MAP
kinase phosphorylate many proteins that control the transcrip-
tion, translation, processing and secretion of inflammatory
mediators.50
Interestingly, the ABIN2 component of Tpl2 complexes
possesses a ubiquitin-binding domain similar to that present in
NEMO,51 but how and whether the binding of ubiquitin chains
to ABIN2 regulates Tpl2 activity is unknown.
How is LUBAC Regulated?
The activation of the MyD88 signalling pathway triggers the
formation of M1-Ub chains within minutes, but the intrinsic E3
ligase activity of LUBAC is not increased.36 These observa-
tions indicate that LUBAC is not converted from an inactive to
an active form by a stable covalent modification, such as
phosphorylation. Instead, as discussed later, the formation of
M1-Ub chains is likely to be triggered by the recruitment of
LUBAC into the MyD88 signalling complex where it is targeted
to its substrates by TRAF6. However, the formation of M1-Ub
chains may be facilitated by the inhibition of Otulin and/or
CYLD (the product of the Cylindromatosis gene), which
appear to be the major deubiquitylases that hydrolyse
M1-Ub chains, as discussed elsewhere in this issue.52
Interestingly, Otulin binds to the PUB (N-terminal peptide:
N-glycanase/UBA- or UBX-containing protein) domain of
HOIP, while CYLD is also recruited to the PUB domain of
HOIP, but indirectly via the protein SPATA2 (spermatogenesis-
associated protein 2).52 The formation and destruction of
M1-Ub chains is therefore catalysed by a single multi-enzyme
complex.
Hybrid Ubiquitin Chains Containing Both M1-Ub and
K63-Ub Linkages
Most of the M1-Ub chains formed in response to IL-1β or the
TLR1/2 agonist Pam3CSK4 are attached covalently to K63-Ub
chains, forming ubiquitin chains containing both types of
linkage, hereafter called K63/M1-Ub ‘hybrids’.36 Some of the
K63/M1-Ub hybrids present in cell extracts are ‘anchored’
covalently to the components of the Myddosome, and most
strikingly to IRAK1 (Figure 1). However, K63/M1-Ub hybrids
that are not ‘anchored’ covalently to any other protein can also
be detected in extracts prepared from IL-1-stimulated cells.36
Whether these ‘unanchored’ K63/M1-Ub hybrids are formed
de novo or generated by cleavage from ‘anchored’K63/M1-Ub
hybrids is unknown. The relative importance of anchored and
unanchored K63/M1-Ub hybrids in activating the TAK1 and
IKK complexes remains to be clarified.
When the M1-Ub chains present in cell extracts are
hydrolysed by incubation with Otulin, the size of the Ub chains
attached to IRAK1 is reduced, but no mono-ubiquitylated
IRAK1 is generated. This finding, together with the reduced
formation of M1-Ub chains in Ubc13-deficient cells, indicates
that IRAK1 is first modified by Lys63-linked ubiquitylation, the
M1-Ub linkages being added subsequently.36 Therefore,
although LUBAC can assemble M1-Ub chains from mono-
meric ubiquitin in vitro, it is K63-Ub oligomers and not
monomeric ubiquitin, which are the substrates first used by
LUBAC when it is recruited into the MyD88 signalling
complex.36 Interestingly, the MyD88-dependent formation of
M1-Ub chains is drastically reduced in TRAF6 KO cells, and
can be restored by the re-expression of wild-type or E3 ligase-
inactive mutants of TRAF6. The specific recognition of K63-
Ub-substrates by LUBAC may be facilitated by the NZF
domains present in HOIP, which interact specifically with K63-
Ub chains in vitro.36,53
The specific hydrolysis of the M1-Ub chains present in
K63/M1-Ub hybrids liberates small K63-Ub oligomers of
varying length and, conversely, the specific hydrolysis of
K63-Ub chains liberates small M1-Ub oligomers of varying
length.36 These experiments demonstrate that the topology of
the K63/M1-Ub hybrids is complex. They also indicate that
once the first M1-Ub linkage has been made to a preformed
K63-Ub oligomer, LUBAC can then use monomeric ubiquitin
as a substrate to add additional M1-Ub linkages. The HOIL-1
component of LUBAC also possesses NZF domains but, in
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Figure 3 The formation of K63/M1-Ub hybrids facilitates the activation of TAK1
and IKK complexes, and the phosphorylation of their substrates. The K63/M1-Ub
hybrids produced by innate immune signalling pathways recruit the TAK1 and IKK
complexes. The interaction of K63-Ub chains with TAB2 and TAB3 activates TAK1
allowing it to phosphorylate and activate MAP kinase kinases 4 and 7 (MKK4, MKK7),
which activate the MAP kinases, termed JNK1 and JNK2. The binding of M1-Ub
chains to NEMO induces a conformational change that permits TAK1 to
phosphorylate IKKβ at Ser177. IKKβ completes the activation process by
phosphorylating itself at Ser181. IKKβ can then activate transcription factors
essential for inflammatory mediator production (NF-κB and IRF5). IKKβ also
activates the Tpl2 kinase complex, which activates MEK1 and MEK2, the protein
kinases that activate ERK1 and ERK2. Tpl2 additionally phosphorylates MKK3 and
MKK6. MKK3 and MKK6 operate redundantly with MKK4 to phosphorylate and
activate p38α in some cells. Protein kinases are highlighted in red, ubiquitin-binding
proteins in purple and ubiquitin (Ub) molecules in blue. Further details are given in
the text
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contrast to those present in HOIP, they bind to M1-Ub
oligomers more strongly than to K63-Ub oligomers.36,54 This
could operate as a positive feedback loop to recruit more
molecules of LUBAC to the MyD88 signalling complex once
the initial M1-Ub linkages have been formed.
Potential Roles of the K63/M1-Ub Hybrids
The formation of hybrid ubiquitin chains containing both K63-
Ub andM1-Ub linkages is not confined to theMyD88 signalling
network, but is a feature of at least three other innate immune
signalling pathways. These include the nucleotide oligomer-
isation domain 1 (NOD1) and NOD2 pathways that are
activated by components of bacterial peptidoglycans, the
TLR3 pathway, which responds to viral double-stranded RNA
and signals via the adaptor protein TRIF (TIR domain-
containing adapter-inducing interferon-β), and the TNF
(tumour necrosis factor) signalling pathway.55,56 These obser-
vations suggest that the formation of K63/M1-Ub hybrids is of
general significance for the regulation of these signal
transduction pathways, raising the question of what their
specific roles might be.
The MyD88, TRIF, NOD1/2 and TNF signalling pathways all
lead to the rapid, TAK1-dependent activation of the canonical
IKK complex. Since the TAB2 and TAB3 components of TAK1
complexes interact specifically with K63-Ub oligomers, and
the NEMO component of the canonical IKK complex binds
selectively to M1-Ub oligomers, the formation of K63/M1-Ub
hybrids may permit the co-recruitment of these two kinase
complexes to the same ubiquitin chains (Figure 3). One role for
the K63/M1-Ub hybridsmay therefore be to facilitate the TAK1-
dependent activation of the IKK complex.37
However, K63/M1-Ub hybrids are likely to control the
activation of innate immune signalling in other ways. For
example, the protein ABIN1 possesses a ubiquitin-binding
domain similar to that present in NEMO.51 ABIN1 restricts the
activation of TAK1 and the canonical IKK complex, probably by
competing with TAB2/3 and NEMO for binding to K63/M1-Ub
hybrids (Figure 4a). The genetic evidence supporting this
hypothesis comes from studies with mice in which the gene
encoding ABIN1 was replaced by the ubiquitin-binding-
defective ABIN1[D485N] mutant. This variant is equivalent to
the NEMO[D311N] mutation discussed earlier. The MyD88-
dependent activation of TAK1, IKKs and MAPKs, and the
production of inflammatory mediators, was enhanced several
fold in dendritic cells and B cells from the ABIN1[D485N]
mice57 (Figure 4b). Interestingly, the ABIN1[D485N] knock-in
mice spontaneously developed an autoimmune disease
similar to Type III and Type IV systemic lupus erythematosus
(SLE) in humans, which can be prevented by crossing the
ABIN1[D485N] mice to MyD88 KO mice.57 This demonstrates
that enhancedMyD88 signalling causes the disease. SLEwas
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Figure 4 ABIN1 restricts the activation of TAK1 and the canonical IKK complex. (a) ABIN1 binds to K63/M1-Ub hybrids and competes with the TAK1 and IKK complexes for
binding to these ubiquitin chains. This suppresses the interaction of the TAK1 and IKK complexes with these ubiquitin chains, restricting their activation and the production of
inflammatory mediators. (b) In dendritic cells and B cells from knock-in mice expressing the ubiquitin-binding-defective ABIN1[D485N] mutant, this restriction is removed, leading
to hyperactivation of the TAK1 and IKK complexes and the overproduction of inflammatory mediators (red arrows). This leads to the spontaneous development of SLE when the
ABIN1[D485N] mice are 4–5 months old. The colour key is as in Figures 1 and 3
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also prevented by crossing ABIN1[D485N] mice to knock-in
mice expressing kinase-inactive mutants of IRAK1 or
IRAK4.58 ABIN1 polymorphisms have been shown to predis-
pose to lupus, psoriasis and other autoimmune diseases in
eight human populations (see Nanda et al.58 for more
information), suggesting that drugs inhibiting IRAK1 and/or
IRAK4 could have therapeutic potential for the prevention and
perhaps the treatment of lupus caused by hyperactivation of
the MyD88 signalling network.
The ABIN1-interacting protein A20 is an immediate early
gene whose expression is increased when the MyD88
signalling pathway is activated, and which also prevents the
overproduction of inflammatory mediators by this pathway.52
The C-terminal domain of A20 contains seven zinc fingers.
The fourth and seventh zinc fingers bind to K63-Ub59,60 and
M1-Ub oligomers,61,62 respectively, making A20 a prime
candidate to interact with K63/M1-Ub hybrids and compete
with the TAK1 and IKK complexes for binding to these
molecules. Since ABIN1 and A20 both interact with K63/M1-
Ub hybrids and with each other,63 ternary complexes formed
between ABIN1, A20 and K63/M1-Ub hybrids may restrict the
activation of the TAK1 and IKK complexes more effectively
than either ABIN1 or A20 alone (Figure 4). These observations
can explain why A20 has been described as a ‘central
gatekeeper’ in inflammation and immunity64 and it also
prevents some types of lymphoma.65
The N-terminal domain of A20 possesses deubiquitylase
activity. It was recently reported that the covalent attachment
of M1-Ub oligomers to K63-Ub oligomers reduces the rate at
which A20 can hydrolyse K63-Ub linkages in vitro, suggesting
a novel role for K63/M1-Ub hybrids in regulating the rate of Ub
chain hydrolysis.66 It was also reported that the IKKβ-
catalysed phosphorylation of A20 enhances the rate at which
A20 hydrolyses K63-Ub chains.66 However, the physiological
significance of the A20 deubiquitylase activity merits further
attention, because other investigators reported that knock-in
mice expressing a deubiquitylase-inactive mutant of A20
appeared normal, with no signs of inflammation. Themice also
had normal proportions of B, T, dendritic and myeloid cells.
Moreover lipolysaccharide and TNF responses, such as
NF-κB activation, were unaffected.67
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